Pfizer’s maternal RSV vaccine candidate accepted for FDA priority review
Article by Emily Kimber 22nd February 2023 PM Live Pfizer’s US application for its respiratory syncytial virus (RSV) maternal vaccine candidate to help protect against the complications of the disease in infants has been accepted for priority review by the US Food and Drug Administration (FDA). The single-dose vaccine is administered in the late second […]